Distinct Electronic Structure for the Extreme Magnetoresistance in YSb

He, Junfeng,Zhang, Chaofan,Ghimire, Nirmal J.,Liang, Tian,Jia, Chunjing,Jiang, Juan,Tang, Shujie,Chen, Sudi,He, Yu,Mo, S.-K.,Hwang, C. C.,Hashimoto, M.,Lu, D. H.,Moritz, B.,Devereaux, T. P.,Chen, Y. L American Physical Society 2016 Physical Review Letters Vol.117 No.26

Effects of Emodin Extracted from Chinese Herbs on Proliferation of Non-small Cell Lung Cancer and Underlying Mechanisms

He, Lin,Bi, Juan-Juan,Guo, Qian,Yu, Yin,Ye, Xiu-Feng Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.4

To aim of this was to observe emodin-mediated cytotoxicity and its influence on Rad51 and ERCC1 expressionin non-small cell lung cancer (NSCLC). NSCLC cells were cultured in vitro with emodin at various concentrations (0, 25, 50, 75 and $100\;{\mu}mol/L$) for 48h and the proliferation inhibition rate was determined by the MTT method. Then, NSCLC were treated with emodin (SK-MES-1 $40\;{\mu}mol/L$, A549 $70\;{\mu}mol/L$) or $20\;{\mu}mol/L$ U0126 (an ERK inhibitor) for 48 h, or with various concentrations of emodin for 48 h and the protein and mRNA expressions of ERCC1 and Rad51 were determined by RT-PCR and Western blot assay, respectively. Emodin exerted a suppressive effect on the proliferation of NSCLC in a concentration dependent manner. Protein and mRNA expression of ERCC1 and Rad51 was also significantly decreased with the dose. Vacuolar degeneration was observed in A549 and SK-MES-1 cell lines after emodin treatment by transmission electron microscopy. Emodin may thus inhibited cell proliferation in NSCLC cells by downregulation ERCC1 and Rad51.

Multiple Large Shareholders and Firm Performance: Evidence from China

Juan Li,Caiyu Yan,Xuefei He,Hongqu He,Tianping Ao 한국증권학회 2023 Asia-Pacific Journal of Financial Studies Vol.52 No.3

Agency theory has shown that multiple large shareholders have competing monitoring and entrenchment governance effects. Therefore, this paper studies the governance effects of multiple large shareholders to determine the dominant effect in the Chinese setting. A panel data model and F-test demonstrate that a significant positive relationship exists between multiple large shareholders and firm performance, but the positive relationship between multiple large shareholders and firm performance will be weakened by state-owned enterprises and politically connected enterprises. Furthermore, our findings suggest that multiple large shareholders can enhance firm performance by mitigating the agent–principal problem and the principal–principal problem. Additionally, a threshold model is introduced to explore the impact of other governance mechanisms on multiple large shareholders’ governance, and our findings show that enhancing controlling shareholder governance and board size significantly weakens multiple large shareholders governance, but increasing the proportion of independent directors strengthens the positive relationship between multiple large shareholders and Tobin’s Q and weakens the positive relationship between multiple large shareholders and ROA.

Preparation and In Vitro Release of Ramose Chitosan-Based-5-Fluorouracil Microspheres

Li, He-Ping,Li, Hui,Wang, Zhou-Dong,Zhang, Juan-Juan,Deng, Man-Feng,Chen, San-Long Korean Chemical Society 2013 대한화학회지 Vol.57 No.1

In order to construct a controlled release system of drugs and to reduce toxic side effects of 5-fluorouracil, the novel ramose chitosan-based-5-fluorouracil microspheres (CS-FU-MS) were prepared. Firstly, using chitosan (CS) as carriers and 5-fluorouracil (5-FU) as a model drug, ramose chitosan-based-5-fluorouracil (CS-FU) was efciently synthesized by chemical crosslinking method through microwave irradiation, drug loading was 10.6%; Secondly, CS-FU-MS were prepared by CS-FU self-assembled under the dialysis conditions and the free 5-FU was encapsulated further at the same time. The size dispersivity of particles is uniform, and the average diameter of the CS-FU-MS was $4{\mu}m$. The drug encapsulation efficiency was 76.1%, and the drug loading was increased to 26.22%. CS-FU-MS maintain the zero-order release time in PBS (pH = 7.4) and HCl/KCl (pH = 1.2) dialysis medium was 40h and 34h respectively, and the cumulative release were 58.89% and 79.33% in 182 h. The results showed that CS-FU-MS have excellent sustained release properties.

Curdione Inhibits Proliferation of MCF-7 Cells by Inducing Apoptosis

Li, Juan,Bian, Wei-He,Wan, Juan,Zhou, Jing,Lin, Yan,Wang, Ji-Rong,Wang, Zhao-Xia,Shen, Qun,Wang, Ke-Ming Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.22

Background: Curdione, one of the major components of Curcuma zedoaria, has been reported to possess various biological activities. It thus might be a candidate anti-flammatory and cancer chemopreventive agent. However, the precise molecular mechanisms of action of curdione on cancer cells are still unclear. In this study, we investigated the effect of curdione on breast cancer. Materials and Methods: Xenograft nude mice were used to detect the effect of curdione on breast cancer in vivo; we also tested the effect of curdione on breast cancer in vitro by MTT, Flow cytometry, JC-I assay, and western blot. Results: Firstly, we found that curdione significantly suppressed tumor growth in a xenograft nude mouse breast tumor model in a dose-dependent manner. In addition, curdione treatment inhibited cell proliferation and induced cell apoptosis. Moreover, after curdione treatment, increase of impaired mitochondrial membrane potential occurred in a concentration dependent manner. Furthermore, the expression of apoptosis-related proteins including cleaved caspase-3, caspase-9 and Bax was increased in curdione treatment groups, while the expression of the anti-apoptotic Bcl-2 was decreased. Inhibitors of caspase-3 were used to confirm that curdione induced apoptosis. Conclusions: Overall, our observations first suggested that curdione inhibited the proliferation of breast cancer cells by inducing apoptosis. These results might provide some molecular basis for the anti-cancer activity of curdione.

Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China

Zhou, Juan,Song, Xing-Bo,He, He,Zhou, Yi,Lu, Xiao-Jun,Ying, Bin-Wu Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.3

Aims: To investigate the distribution of epidermal growth factor receptor (EGFR) mutations, and explore any relationships with clinical characteristics in non-small-cell lung carcinoma (NSCLC) patients. Materials and Methods: EGFR mutations were assessed by ADx-ARMS in 261 NSCLC patients from West China Hospital of Sichuan University. Relationships between EGFR mutation and clinical characteristics were analyzed by SPSS. Results: The EGFR mutation rate was 48.7% (127/261), 19-del and L858R mutations occurred predominantly, accounting for 33.1% and 40.9%, respectively, in mutated cases. Moreover, 10.2% patients were found to carry double mutations. EGFR mutations occurred more frequently in women (57.5%) than in men (41.8%) (P=0.01), and were more frequent in non-smokers (61.2%) than in former or current smokers (31.2%) (P<0.00). In addition, they were more common in adenocarcinomas (52.8%) and adenosquamous carcinomas (42.8%) than in squamous cell carcinomas (14.8%) (p<0.00). However, only smoking history and pathological types, rather than gender, proved to be associated with EGFR mutations on multivariate logistic regression analysis. No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) - 19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas. Conclusions: The EGFR mutation rate was 48.7% in NSCLCs in Southwest China, so that nearly 40% patients might benefit from targeted therapies. Smoking status and pathological types were independent predictors of EGFR mutation, while EGFR mutation type was related to only pathological type, rather than smoking status.

Association of CYP2C19 Polymorphisms with Survival of Breast Cancer Patients Using Tamoxifen: Results of a Meta-analysis

Bai, Lan,He, Juan,He, Gong-Hao,He, Jian-Chang,Xu, Fan,Xu, Gui-Li Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.19

Background: Previous studies accessing the association of CYP2C19 with outcomes of patients using tamoxifen for breast cancer have yielded conflicting results. The aim of this meta-analysis is to obtain a more precise estimate of effects of CYP2C19 polymorphisms and to clarify their effects on survival of the breast cancer patients using tamoxifen. Materials and Methods: A systematic search of PubMed and Embase was performed, comparing patients with or without $CYP2C19^*2$ and $CYP2C19^*17$, relevant articles searched for. The following outcomes were included from the eligible studies: disease-free survival (DFS) and overall survival (OS), expressed by hazard ratios (HR) with corresponding 95% confidence interval (CI). Subgroup analysis by genotypes was also performed. Pooled estimates were calculated using random-effect model in accordance to the heterogeneity. Results: Six studies met the inclusion criteria. The integrated OR on the association between CYP2C19 and DFS, calculated by the random-effect model, was 0.54 (95%CI=0.34-0.84, p=0.013). Subgroup analysis showed that both $CYP2C19^*2$ and $CYP2C19^*17$ were associated with increased survival. The pooled results of two studies for OS were OR=0.46 (95%CI=0.21-1.01, p=0.233). Conclusions: This meta-analysis suggests that the $CYP2C19^*2$ and $CYP2C19^*17$ genotypes are associated with increased survival in breast cancer patients using tamoxifen.

KIF11 Functions as an Oncogene and Is Associated with Poor Outcomes from Breast Cancer

Juan Zhou,Wei-Rong Chen,Li-Chao Yang,Jun Wang,Jia-Yuan Sun,Wen-Wen Zhang,Zhen-Yu He,San-Gang Wu 대한암학회 2019 Cancer Research and Treatment Vol.51 No.3

Purpose The study aimed to search and identify genes that were differentially expressed in breast cancer, and their roles in cancer growth and progression. Materials and Methods The Gene Expression Omnibus (Oncomine) and The Cancer Genome Atlas databases (https://cancergenome.nih.gov/) were screened for genes that were expressed differentially in breast cancer and were closely related to a poor prognosis. Gene expressions were verified by quantitative real-time polymerase chain reaction, and genes were knocked down by a lentivirus-based system. Cell growth and motility were evaluated and in vivo nude mice were used to confirm the in vitro roles of genes. Markers of epithelial-to-mesenchymal transition and the associations of KIF11 with the classical cancer signaling pathways were detected by Western blot. Results A series of genes expressed differentially in patients with breast cancer. The prognosis associated with high KIF11 expression was poor, and the expression of KIF11 increased significantly in high stage and malignant tumor cells. Inhibiting KIF11 expression in lentivirussuppressed cells revealed that KIF11 inhibition significantly reduced cell viability and colony formation, inhibited migration and invasion, but promoted apoptosis. The sizes and weights of KIF11-inhibited tumors in nude mice were significantly lower than in the negative controls. Western blot showed that E-cadherin in breast cancer was significantly upregulated in KIFinhibited cells and tumor tissues, whereas N-cadherin and vimentin were significantly downregulated. BT549 and MDA231 cells with KIF11 knockdown exhibited decreased ERK, AMPK, AKT, and CREB phosphorylation. Conclusion KIF11 acts as a potential oncogene that regulates the development and progression of breast cancer.

Enhanced photoelectric properties of n-ZnO NWs/p-Si heterojunction LEDs by inserting an insulating MgO layer using sol-gel method

Juan Yao,Guotao Lin,Zhenxi Du,Jun Liang,Huan He,Xiaoming Shen,Yuechun Fu 대한금속·재료학회 2021 ELECTRONIC MATERIALS LETTERS Vol.17 No.4

ZnO nanowires (ZnO NWs) were synthesized by hydrothermal method on Si (100) substrates, in which an insulating MgOlayer deposited using sol–gel method was inserted between the seed layer and Si substrate. The eff ects of MgO layer on themicrostructure, luminescence and electrical properties of ZnO NWs as well as n-ZnO NWs/p-Si heterojunction LEDs wereinvestigated. With the insertion of MgO layer, well-aligned ZnO NWs with good crystalline quality are obtained, which canbe attributed to the smooth seed layer with homogeneous globular particles. The electroluminescence spectra of n-ZnO NWs/MgO/p-Si heterojunction LEDs exhibit a broad emission band from near ultraviolet to yellow-green region. n-ZnO NWs/MgO/p-Si heterojunction also shows an enhanced ultraviolet photoluminescence effi ciency, and its defect-related visibleemission is greatly suppressed compared with that of n-ZnO NWs/p-Si heterojunction. The current–voltage curves of bothheterojunction LEDs present a typical rectifying behavior, but the rectifi cation ratio increases almost 5 times by insertingMgO layer, which is ascribed to a reduction in the leakage current under reverse bias voltage.

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea

Juan Zhou,San-Gang Wu,Jun-Jie Wang,Jia-Yuan Sun,Fengyan Li,Qin Lin,Huan-Xin Lin,Zhen-Yu He 대한암학회 2015 Cancer Research and Treatment Vol.47 No.1

Purpose The purpose of this study was to assess the value of ovarian ablation using goserelin inpremenopausal patients with stage II/III hormone receptor-positive breast cancer withoutchemotherapy-induced amenorrhea (CIA). Materials and MethodsWe retrospectively reviewed the data of breast patients treated between October 1999 andNovember 2007 without CIA. The Kaplan-Meier method was used for calculation of thesurvival rate. Log rank method and Cox regression analysis were used for univariate andmultivariate prognostic analysis. ResultsThe median follow-up period was 61 months. Initially, 353 patients remained without CIAafter chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). Inunivariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9%vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006),disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5%vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independentfactor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311;95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantlyimproved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) inpatients aged < 40 years. In patients aged  40 years, goserelin only improved DMFS(p=0.028) and DFS (p=0.027). ConclusionOvarian ablation with goserelin plus TAM resulted in significantly improved therapeuticefficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancerwithout CIA.